Research guide for for men — mechanisms, protocols, and independent analysis from Compound Review.
How PT-141 Works in Men
PT-141 (Bremelanotide) is a melanocortin receptor agonist (MC3R and MC4R) that acts centrally on the hypothalamus to initiate sexual arousal. Unlike PDE5 inhibitors (sildenafil, tadalafil), PT-141 does not act on the vascular system — it works through the CNS sexual arousal pathway, making it effective in men with psychogenic erectile dysfunction and in those who do not respond to PDE5 inhibitors. It received FDA approval in 2019 for hypoactive sexual desire disorder in premenopausal women (Vyleesi).
PT-141 Dosage Protocol for Men
For men, research protocols use 1.75 mg subcutaneously 45 minutes before sexual activity. Some protocols use lower doses (0.5–1.25 mg) to minimize side effects. PT-141 is not intended for daily use — it is an on-demand compound. Nausea is the most common side effect (reported in ~40% of subjects in clinical trials) and is dose-dependent. Transient blood pressure elevation has been observed; it is contraindicated with high-risk cardiovascular conditions.
PT-141 vs PDE5 Inhibitors for Men
PT-141's FDA approval for women provides the strongest clinical evidence base of any peptide in this category. Male-specific trials have demonstrated efficacy in erectile dysfunction and sexual desire, though the compound is not FDA-approved for men. Off-label use in men is supported by the shared melanocortin mechanism. It is available by prescription in some jurisdictions.